The role of immunomodulatory medications in the treatment of COVID-19.
Curr Opin Rheumatol
; 33(5): 431-445, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2279944
ABSTRACT
PURPOSE OF REVIEW Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies. RECENT FINDINGS:
Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations.SUMMARY:
Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Antirreumáticos
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio experimental
/
Ensayo controlado aleatorizado
Límite:
Humanos
Idioma:
Inglés
Revista:
Curr Opin Rheumatol
Asunto de la revista:
Reumatología
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS